• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Alios BioPharma

edit

Alios is discovering and developing novel therapeutic agents based on three platform technologies including: small molecule activators of innate immunity antiviral pathways (RNase L activation), phosphate protected nucleotide prodrug chemistry, and glycoprotein-engineering of interferons (Glycoferonâ). This complementary group of platform technologies has the potential to generate a number of distinct therapeutic products to treat a variety of serious viral infections such as chronic hepatitis B and C, HIV infection, and respiratory viruses (e.g. pandemic influenza) and emerging viral diseases (e.g. SARS).

Milestones

edit

• 
  Alios BioPharma received $8M in Series A funding. (6/11/09)
  Posted 6/12/09 at 8:28am via fiercebiotech.com
• 
  Alios BioPharma received $24M in Series A funding. (2/12/09)
  Posted 4/17/09 at 4:11am via aliosbiopharma.com

Videos

Screenshots

edit

Above: Home page
Uploaded: 5/13/09

Sources

1. Alios BioPharma, Inc. Completes First Closing of Series A Financing with Commitment of $24 MM from 3 (aliosbiopharma.com) [edit]
2. Alios raises another $8M (fiercebiotech.com) [edit]